Patients receiving neuromuscular blocking agents during anesthesia should be carefully monitored using quantitative approaches to ensure safety and optimal outcomes, according to recently released guidelines from the American Society of Anesthesiologists (ASA) and the European Association of Anaesthesiology and Intensive Care (ESAIC).
In a joint letter to the editor published in Anesthesiology, experts from both groups highlighted the importance of the guidelines, which were based on thorough,